|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1445 New York Avenue, NW, #800 |
Address2 |
|
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1331-12
|
||||||||
|
6. House ID# 303290000
|
TYPE OF REPORT | 8. Year | 2017 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shawn Friesen |
Date | 10/20/2017 2:21:33 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting.
Lobby members of Congress regarding issues related to telemedicine.
Advocate for increased transparency regarding drug pricing.
Lobby members of the House to join the Congressional Skin Cancer Caucus.
Advocate for the sense of Congress that states should expand access to sun safety products and practices.
Lobby members of Congress to support H. Res. 282 to encourage proper sun safety practices for youth under care of schools and camps.
Advocate for adequate and accurate network coverage for dermatologic care within health insurance exchange networks.
Advocate for generic drug approval reform in H.R. 2430 /S. 934, FDA Reauthorization Act.
Support H.R. 749, the Lower Drug Costs through Competition Act.
Support H.R. 2871, Preserving Patient Access to Compounded Medications Act.
Support H.R. 2077, Restoring Patients Voice Act.
Support H.R. 1316, Prescription Drug Price Transparency Act.
Support H.R. 2051, Fair Access for Safe and Timely Generics Act.
Support H.R. 2212/S. 974, Creating and Restoring Equal Access to Equivalent Samples Act.
Support H.R. 2999, Patients Access to Treatments Act.
Support S. 637, C-THRU Act.
Support S. 297, Increasing Competition in Pharmaceuticals Act.
Support S. 989, Ensuring Childrens Access to Specialty Care Act
Support pediatric subspecialty loan repayment in any reauthorization of the Title VII programs.
Advocate for reform of insurers prior authorization practices.
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program.
17. House(s) of Congress and Federal agencies Check if None
Food & Drug Administration (FDA), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3628/S. 1603).
Educate members of Congress regarding Carter Amendment (#7) to Division B of Rules Committee Print 115-31 related to access to compounded medications (H.R. 3628, FY 18 Agriculture Appropriations Bill).
Advocate for the inclusion of Congressional Directed Medical Research Programs in the 2018 National Defense Authorization Act (S. 1519/H.R. 2810). Advocate against Sections 733, 891, 892, and 893 in S. 1519, which would impact CDMRP.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3628).
Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month".
Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to repeal the PHHF in H.R. 1628 (American Health Care Act/Better Care Reconciliation Act).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocate for adequate and accurate network coverage for dermatologic care within Medicare Advantage.
Support legislation to eliminate the Independent Payment Advisory Board (H.R. 849, Protecting Seniors Access to Medicare Act, H.J. Res. 51, S.251, Protecting Medicare from Executive Action Act, S. 260, Protecting Seniors Access to Medicare Act, S.J. Res. 16 and S.J. Res. 17)
Advocate for increased funding and reforms to Graduate Medical Education.
Advocate for a new study on physician shortage to be conducted by the Health Resources and Services Administration.
Lobby members of Congress regarding improvements to Health Information Technology implementation.
Support H.R. 2556/ S. 1016, CONNECT for Health Act of 2017.
Lobby members of Congress regarding issues related to telemedicine and Medicare reimbursement, including regarding provisions in H.R. 2556/S.1016, CONNECT for Health Act of 2017 and S. 2870, Creating High-Quality Results and Outcomes Necessary to Improve (CHRONIC) Care Act of 2017.
Advocate for improving disease management and care coordination for patients with chronic diseases.
Support preservation of the In-Offices Ancillary Services Exemption (IOASE) under Stark Law regarding physician self-referral and oppose repeal of the in-office ancillary and physician services exception.
Advocate regarding possible changes to IOASE and Stark Law relative to implementation of Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110)
Advocate for Congressional support for relief from Medicare regulations under Medicare Access and CHIP Reauthorization Act (MACRA P.L. 114-110), including the Quality Payment Program (QPP) and specifically the development of advanced alternative payment models (APMs) and implementation of the Merit-Based Incentive Payment System (MIPS).
Advocate allowing further appeals process within the Quality Payment Program.
Advocate against H.R. 2066, Promoting Integrity in Medicare Act of 2017.
Advocate for reform of insurers prior authorization practices within Medicare Advantage and Medicare prescription drug plans (Medicare Parts C and D).
Advocate expanding the period for reporting and returning overpayments beyond the 60 days statutorily required under audits by Recovery Audit Contractors (RACs).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOR
16. Specific lobbying issues
Advocate for legislation to enact medical liability reforms.
Support H.R. 1704, Accessible Care by Curbing Excessive lawSuitS (ACCESS) Act.
Support H.R. 1215, Protecting Access to Care Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Advocate against the repeal of the tanning tax provision under the Better Care Reconciliation Act of 2017 (H.R. 1628).
Advocate against H.R. 1150, the Tanning Tax Repeal Act of 2017, to repeal excise tax on indoor tanning services.
Advocate for legislation that would allow for Flexible Spending Accounts (FSAs) to be used to cover over-the-counter (OTC) drugs (S.85/H.R. 394, Restoring Access to Medication Act).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Blake |
McDonald |
|
|
|
Michelle |
Mathy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code IMM
16. Specific lobbying issues
Support legislation, such as, S. 1615/ H.R. 3440 DREAM Act, which would enable those individuals eligible with Deferred Action for Childhood Arrivals status are able to continue their employment, education, training, and research.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Michelle |
Mathy |
|
|
|
Blake |
McDonald |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3628/S. 1603).
Educate members of Congress regarding Carter Amendment (#7) to Division B of Rules Committee Print 115-31 related to access to compounded medications (H.R. 3628, FY 18 Agriculture Appropriations Bill).
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3628).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Michelle |
Mathy |
|
|
|
Blake |
McDonald |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Lobby members of Congress to conduct oversight of implementation of Public Law 113-54, the Drug Quality and Security Act and to protect and preserve the use of compounded pharmaceuticals in the physician office prior to receipt of a patient prescription.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting.
Support H.R. 2871, Preserving Patient Access to Compounded Medications Act.
Support H.R. 1316, Prescription Drug Price Transparency Act
Support S. 637, C-THRU Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Michelle |
Mathy |
|
|
|
Blake |
McDonald |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Advocate for access to dermatological procedures for veterans through the Veterans Choice Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shawn |
Friesen |
|
|
|
Christine |
O'Connor |
|
|
|
Michelle |
Mathy |
|
|
|
Blake |
McDonald |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |